« Back
Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover
06/27/17 8:30 AM EDT
The 60,000 square foot state-of-the-art facility significantly enhances Sarepta’s research and manufacturing capabilities as it expands its global commercial footprint and rapidly advances its Duchenne muscular dystrophy (DMD) pipeline, which comprises a robust exon skipping platform, and next generation approaches such as gene therapy and utrophin upregulation programs. The current focus of the manufacturing facility will be to advance Sarepta’s development pipeline and research programs. By the end of the year, Sarepta could have up to seven investigational DMD treatments in the clinic.
Ultimately, Sarepta’s goal is to help as many individuals with DMD as possible. To support this objective, Sarepta plans to expand its headcount in
“Since first moving to
Several state and industry officials are scheduled to speak at the ceremony, including the Honorable Charles D. Baker, Massachusetts’ Governor,
“Massachusetts’ growing advanced-manufacturing sector and robust life sciences industry continue to drive our nation-leading innovation economy,” said Governor Baker. “We look forward to the advances in treatment Sarepta will generate for patients and families impacted by DMD as they expand their footprint and manufacturing capacity in the Commonwealth.”
“Massachusetts is a great place to work and live,” said Mr. McCready. “The opening of Sarepta’s
Mr. Coughlin stated, “Congratulations to Sarepta on this exciting announcement. Their creation of a research and manufacturing facility in
About Sarepta Therapeutics
Forward-Looking Statement
This press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "in-tends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements about the current focus of the manufacturing facility in
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Known risk factors include, among others: Sarepta may not be able to have up to seven investigational DMD treatments in the clinic by the end of the year due to challenges and uncertainties inherent in research and development; and Sarepta may not be able to expand its headcount by the expected rate in the expected timeframe due to uncertainties related to Sarepta business and human resources.
Any of the foregoing risks could adversely affect Sarepta's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's 2016 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q for the quarter ended
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source:
Media and Investors:Sarepta Therapeutics, Inc. Ian Estepan , 617-274-4052 iestepan@sarepta.com orW2O Group Brian Reid , 212-257-6725 breid@w2ogroup.com
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.